For research use only. Not for therapeutic Use.
MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (Ki=7.9 nM for hOGA) with excellent CNS penetration[1].
MK-8719 has excellent intrinsic potency and selectivity, improved Papp, high CNS exposure, good pharmacokinetics, favorable metabolic stability, and robust pharmacodynamic response[1].
| Catalog Number | I032405 |
| CAS Number | 1382799-40-7 |
| Synonyms | (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol |
| Molecular Formula | C9H14F2N2O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C9H14F2N2O3S/c1-2-12-9-13-3-4(14)5(15)6(7(10)11)16-8(3)17-9/h3-8,14-15H,2H2,1H3,(H,12,13)/t3-,4-,5+,6+,8-/m1/s1 |
| InChIKey | UDQTXCHQKHIQMH-KYGLGHNPSA-N |
| SMILES | CCNC1=NC2C(C(C(OC2S1)C(F)F)O)O |
| Reference | [1]. Selnick HG, et al. Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Sep 29. |
